B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
B cell depletion therapies in autoimmune disease: advances and mechanistic insights.
复制标题
自身免疫性疾病的B细胞耗竭治疗：进展和机制洞察。
DOI：
10.1038/s41573-020-00092-2
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Gommerman JL
中科院分区：
文献类型：
--
作者：
Lee DSW;Rojas OL;Gommerman JL
在过去的15年里，B细胞被重新发现不仅是旁观者，而且是自身免疫病因学的积极参与者。这在一定程度上是由B细胞耗竭疗法(BCDT)的临床成功推动的。最初被认为是一种消除癌症B细胞的方法，BCDT，如针对CD20，CD19和BAFF的BCDT现在被用于治疗自身免疫疾病，包括系统性红斑狼疮和多发性硬化症。BCDT在自身免疫性疾病中的应用带来了一些惊喜。例如，尽管抗体分泌浆细胞被认为在自身免疫性疾病中具有负面致病作用，但BCDT即使控制了疾病，对这些细胞和抗体水平的影响也是有限的。在这篇综述中，我们更新了我们对B细胞生物学的理解，回顾了在自身免疫适应症中使用BCDT的临床试验结果，讨论了BCDT作用机制的假设，并推测了针对B细胞以外耗竭的不断发展的策略。在自身免疫条件下检测B细胞耗竭疗法(BCDT)，这是一种被批准的治疗B细胞恶性肿瘤的方法，为基础B细胞生物学提供了关键的见解。在这篇综述中，Gommerman和他的同事讨论了BCDT在自身免疫条件下的作用，强调了BCDT在临床上有效的疾病，以及BCDT在自身免疫条件下尚未有效的潜在和陷阱。
In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather active participants in autoimmune aetiology. This has been fuelled in part by the clinical success of B cell depletion therapies (BCDTs). Originally conceived as a method of eliminating cancerous B cells, BCDTs such as those targeting CD20, CD19 and BAFF are now used to treat autoimmune diseases, including systemic lupus erythematosus and multiple sclerosis. The use of BCDTs in autoimmune disease has led to some surprises. For example, although antibody-secreting plasma cells are thought to have a negative pathogenic role in autoimmune disease, BCDT, even when it controls the disease, has limited impact on these cells and on antibody levels. In this Review, we update our understanding of B cell biology, review the results of clinical trials using BCDT in autoimmune indications, discuss hypotheses for the mechanism of action of BCDT and speculate on evolving strategies for targeting B cells beyond depletion. Examining B cell depletion therapy (BCDT), an approved treatment for B cell malignancies, in autoimmune conditions has provided key insights into basic B cell biology. In this Review, Gommerman and colleagues discuss BCDT in autoimmune conditions, highlighting diseases in which BCDT has been clinically effective and the potential and pitfalls for BCDT in autoimmune conditions in which it has not yet been efficacious.
登录
查看更多内容
影响因子：
9.1
作者：
Agrawal, Sudhanshu;Gupta, Sudhir
通讯作者：
Gupta, Sudhir
影响因子：
30.5
作者：
Bermejo, Daniela A.;Jackson, Shaun W.;Gorosito-Serran, Melisa;Acosta-Rodriguez, Eva V.;Amezcua-Vesely, Maria C.;Sather, Blythe D.;Singh, Akhilesh K.;Khim, Socheath;Mucci, Juan;Liggitt, Denny;Campetella, Oscar;Oukka, Mohamed;Gruppi, Adriana;Rawlings, David J.
通讯作者：
Rawlings, David J.
影响因子：
9.9
作者：
Bar-Or, Amit;Grove, Richard A.;Sorensen, Per S.
通讯作者：
Sorensen, Per S.
影响因子：
7.3
作者：
Bell, Luisa;Lenhart, Alexander;Berberich-Siebelt, Friederike
通讯作者：
Berberich-Siebelt, Friederike
DOI：
10.4049/jimmunol.1001431
发表时间：
2010-09-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Barr TA;Brown S;Mastroeni P;Gray D
通讯作者：
Gray D